Equities research analysts expect Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) to announce sales of $26.57 million for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Lexicon Pharmaceuticals’ earnings. The lowest sales estimate is $20.95 million and the highest is $37.09 million. Lexicon Pharmaceuticals posted sales of $23.04 million during the same quarter last year, which would indicate a positive year over year growth rate of 15.3%. The business is scheduled to report its next earnings report on Friday, March 2nd.
According to Zacks, analysts expect that Lexicon Pharmaceuticals will report full year sales of $26.57 million for the current financial year, with estimates ranging from $78.94 million to $94.37 million. For the next fiscal year, analysts forecast that the firm will report sales of $124.25 million per share, with estimates ranging from $110.64 million to $136.00 million. Zacks’ sales averages are an average based on a survey of research firms that cover Lexicon Pharmaceuticals.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.07. Lexicon Pharmaceuticals had a negative return on equity of 111.68% and a negative net margin of 165.69%. The firm had revenue of $26.94 million during the quarter, compared to analysts’ expectations of $27.97 million. During the same quarter last year, the business posted ($0.35) earnings per share. The firm’s revenue was down 2.8% on a year-over-year basis.
Several analysts recently issued reports on the company. Cowen and Company reiterated a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Tuesday, August 1st. Wedbush reiterated an “ourperform” rating and set a $39.00 target price on shares of Lexicon Pharmaceuticals in a research report on Monday, August 7th. BidaskClub cut Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, August 2nd. Needham & Company LLC reiterated a “buy” rating and set a $21.00 target price on shares of Lexicon Pharmaceuticals in a research report on Sunday, September 17th. Finally, Zacks Investment Research cut Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 17th. One analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the stock. Lexicon Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $28.75.
COPYRIGHT VIOLATION NOTICE: “$26.57 Million in Sales Expected for Lexicon Pharmaceuticals, Inc. (LXRX) This Quarter” was originally published by Transcript Daily and is owned by of Transcript Daily. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://transcriptdaily.com/2017/11/22/26-57-million-in-sales-expected-for-lexicon-pharmaceuticals-inc-lxrx-this-quarter.html.
Lexicon Pharmaceuticals (NASDAQ LXRX) traded down $0.13 during trading hours on Friday, hitting $9.57. The company had a trading volume of 927,896 shares, compared to its average volume of 811,817. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.66 and a quick ratio of 1.65. Lexicon Pharmaceuticals has a 12-month low of $8.07 and a 12-month high of $18.00.
In other news, Director Public Equities L.P. Invus purchased 180,727 shares of the company’s stock in a transaction that occurred on Friday, November 17th. The stock was bought at an average cost of $10.11 per share, with a total value of $1,827,149.97. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Lonnel Coats purchased 30,000 shares of the company’s stock in a transaction that occurred on Friday, September 15th. The shares were purchased at an average cost of $12.54 per share, with a total value of $376,200.00. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 945,353 shares of company stock valued at $9,304,953. 5.77% of the stock is owned by corporate insiders.
A number of institutional investors have recently made changes to their positions in LXRX. Cubist Systematic Strategies LLC bought a new position in Lexicon Pharmaceuticals during the third quarter valued at approximately $149,000. Parametric Portfolio Associates LLC bought a new stake in shares of Lexicon Pharmaceuticals in the 2nd quarter valued at approximately $182,000. C WorldWide Group Holding A S lifted its stake in shares of Lexicon Pharmaceuticals by 49.6% in the 3rd quarter. C WorldWide Group Holding A S now owns 16,146 shares of the biopharmaceutical company’s stock valued at $198,000 after purchasing an additional 5,353 shares during the last quarter. First Mercantile Trust Co. lifted its stake in shares of Lexicon Pharmaceuticals by 11.2% in the 2nd quarter. First Mercantile Trust Co. now owns 12,212 shares of the biopharmaceutical company’s stock valued at $201,000 after purchasing an additional 1,227 shares during the last quarter. Finally, Cim Investment Mangement Inc. bought a new stake in shares of Lexicon Pharmaceuticals in the 2nd quarter valued at approximately $262,000.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.